- An anonymous donation funds an Expanded Access Program (EAP) for Cognition Therapeutics' drug treatment zervimesine (CT1812).
- The program supports approximately 30 patients with dementia with Lewy bodies (DLB), providing 100 mg zervimesine daily.
- Dr. James Galvin leads the program, with Banner Sun Health Research Institute in Arizona as the first of eight participating sites.
Cognition Therapeutics, Inc. (CGTX, Financial), a clinical-stage biopharmaceutical company, announced the receipt of an anonymous philanthropic donation to fund an expanded access program (EAP) for its investigational drug, zervimesine (CT1812), aimed at treating dementia with Lewy bodies (DLB). Initial funding will enable approximately 30 patients to participate, receiving 100 mg of oral zervimesine daily for about one year.
Dr. James Galvin, a noted expert in Lewy body dementia, will serve as the lead investigator for this multi-center, open-label program. The Banner Sun Health Research Institute in Arizona has been activated as the first of eight U.S. sites selected for the EAP, which will include sites involved in the previous SHIMMER study.
The expanded access program is open to eligible participants from the SHIMMER study, as well as new patients diagnosed with mild-to-moderate DLB who meet the program's criteria. The launch of this program marks a significant step in providing real-world evidence for zervimesine's clinical development pathway, potentially accelerating its timeline and showcasing the potential efficacy of this novel treatment approach.
